Actively Recruiting
Randomized Study Comparing Neratinib Alone Versus Neratinib with Palbociclib in Patients With HER2 Positive Gynecologic Cancers and Other Solid Tumors
Led by National Cancer Institute (NCI) · Updated on 2026-11-02
70
Participants Needed
194
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of neratinib alone versus a combination of neratinib and palbociclib in patients with HER2 positive solid tumors, including gynecologic cancers. This Phase II trial aims to compare the progression-free survival between these treatments, as both drugs belong to a class called kinase inhibitors that block cancer cell growth signals. The study also explores additional outcomes such as response rates, overall survival, and side effects. Participants are randomly assigned to one of two treatment groups. One group receives neratinib orally daily on specific days of each 28-day cycle, with the possibility to switch to the combination treatment if their disease progresses. The second group receives both neratinib and palbociclib with defined daily dosing schedules within each cycle. During the trial, patients undergo various scans including echocardiograms, CT or MRI scans, and blood sample collections. Tumor biopsies may also be performed before and during treatment. After finishing the study treatments, patients are followed every three months for two years. Throughout the study, participants will have regular assessments to monitor their cancer status and therapy effects. This includes imaging to evaluate tumor response, blood tests to collect biological samples, and cardiac function evaluations. Researchers will measure progression-free survival as the primary outcome and overall survival as a secondary outcome. Safety will be monitored by tracking adverse events, especially serious toxicities. The total participation time includes treatment cycles and a two-year follow-up period to observe long-term outcomes.
CONDITIONS
Brief Title
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here